TRESIBA Drug Insight

“TRESIBA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about TRESIBA for type 1 diabetes mellitus in the seven major markets. A detailed picture of the TRESIBA for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TRESIBA for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TRESIBA market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary

TRESIBA is a long-acting human insulin analog indicated to improve glycemic control in patients aged 1-year and older with type 1 diabetes mellitus. The primary activity of insulin, including TRESIBA, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis and enhances protein synthesis. TRESIBA forms multi hexamers when injected into the SC tissue resulting in a SC insulin degludec depot. The protracted time action profile of TRESIBA is predominantly due to delayed absorption of insulin degludec from the SC tissue to the systemic circulation and a lesser extent, due to the binding of insulin degludec to circulating albumin.

Dosage and administration

The recommended starting dose of TRESIBA in insulin naïve patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as a short-acting insulin and divided between each daily meal. As a general rule, 0.2–0.4 units of insulin per kilogram of body weight can be used to calculate the initial daily insulin dose in insulin naïve patients with type 1 diabetes.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TRESIBA description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on TRESIBA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TRESIBA research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TRESIBA.
• The report contains forecasted sales of TRESIBA for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for TRESIBA in type 1 diabetes mellitus.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TRESIBA Analytical Perspective by DelveInsight

• In-depth TRESIBA Market Assessment

This report provides a detailed market assessment of TRESIBA for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• TRESIBA Clinical Assessment

The report provides the clinical trials information of TRESIBA for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TRESIBA dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to TRESIBA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRESIBA in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of TRESIBA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TRESIBA in type 1 diabetes mellitus.

Key Questions

• What is the product type, route of administration and mechanism of action of TRESIBA?
• What is the clinical trial status of the study related to TRESIBA in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TRESIBA development?
• What are the key designations that have been granted to TRESIBA for type 1 diabetes mellitus?
• What is the forecasted market scenario of TRESIBA for type 1 diabetes mellitus?
• What are the forecasted sales of TRESIBA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to TRESIBA for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?